<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To explore whether human albumin (Alb) administration prior to thrombolysis with recombinant tissue plasminogen activator (rt-PA) can eliminate brain damage induced by this treatment given after the effective and safe window of 3h after <z:hpo ids='HP_0001297'>stroke</z:hpo> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Rats were subjected to embolic <z:hpo ids='HP_0001297'>stroke</z:hpo> by unilateral embolic middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) </plain></SENT>
<SENT sid="2" pm="."><plain>Three or six hours after the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0001297'>stroke</z:hpo>, rats were administered intravenously with saline (control), rt-PA (thrombolysis) or rt-PA+Alb (additional Alb 3h after MCAO, combination) </plain></SENT>
<SENT sid="3" pm="."><plain>Cerebral blood flow, <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, space-occupying effect and blood brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) leakage of <z:chebi fb="0" ids="31797">gadopentetate dimeglumine</z:chebi> (Gd-<z:chebi fb="0" ids="35739">DTPA</z:chebi>) were assessed dynamically by magnetic resonance imaging (MRI) at 24h, 7 and 14days after treatment </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="2" ids="33602">BBB</z:chebi> leakage of both fluoro-isothiocyanate <z:chebi fb="0" ids="52071">dextran</z:chebi> (<z:chebi fb="0" ids="37926">FITC</z:chebi>-<z:chebi fb="0" ids="52071">dextran</z:chebi>) and erythrocytes was also evaluated 14days after treatment </plain></SENT>
<SENT sid="5" pm="."><plain>The space-occupying effect in the combination group at 7days after treatment declined significantly compared with that at 24h after treatment (P&lt;0.05), but additional Alb treatment failed to reduce the <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes or improve cerebral blood volume </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, <z:chebi fb="2" ids="33602">BBB</z:chebi> leakage of both small (Gd-<z:chebi fb="0" ids="35739">DTPA</z:chebi>) and large (<z:chebi fb="0" ids="37926">FITC</z:chebi>-<z:chebi fb="0" ids="52071">dextran</z:chebi> and erythrocytes) molecules decreased significantly in the combination compared to the saline or thrombolysis groups (P&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>Alb administration prior to thrombolysis (3h after <z:hpo ids='HP_0001297'>stroke</z:hpo>) can reduce delayed rt-PA treatment-induced <z:hpo ids='HP_0002181'>brain edema</z:hpo> and <z:chebi fb="2" ids="33602">BBB</z:chebi> permeability </plain></SENT>
</text></document>